glp-1 medicaid coverage GLP-1s and The Payer Predicament Patients Face New Barriers for

Some copycats provided by medical spas and wellness clinics have been deemed risky since they use a different type of substance compared to the branded drug formulas

Search parameters included: two allowed missed cleavages, mass tolerances of 4.5 ppm and 20 ppm for precursor and fragment ions, carbamidomethylation of cysteine as a fixed modification, acetylation of the N-terminal residue and oxidation of methionine as variable modifications, and a false discovery rate of 0.01 for both peptides and proteins

Green et al., 2006

Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results

Semaglutide (Wegovy) has been granted FDA approval for the treatment of metabolic-associated steatohepatitis (MASH, or NASH with fibrosis)

If any signs of injection site infection develop (increasing redness, warmth, swelling, or pain), discontinue use and consult a healthcare provider